Amit Kumar Buys 43,000 Shares of Anixa Biosciences, Inc. (NASDAQ:ANIX) Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Amit Kumar bought 43,000 shares of the stock in a transaction on Wednesday, January 15th. The stock was bought at an average price of $2.23 per share, for a total transaction of $95,890.00. Following the completion of the purchase, the chief executive officer now directly owns 559,925 shares in the company, valued at approximately $1,248,632.75. The trade was a 8.32 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Anixa Biosciences Price Performance

Shares of ANIX stock opened at $2.58 on Friday. The business’s fifty day moving average price is $2.84 and its 200 day moving average price is $3.02. The firm has a market capitalization of $83.02 million, a PE ratio of -6.62 and a beta of 0.90. Anixa Biosciences, Inc. has a 1-year low of $2.07 and a 1-year high of $5.13.

Anixa Biosciences (NASDAQ:ANIX) last announced its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.02. Equities research analysts expect that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ANIX has been the topic of a number of analyst reports. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Anixa Biosciences in a research report on Tuesday, November 19th. D. Boral Capital reiterated a “buy” rating and set a $10.00 price target on shares of Anixa Biosciences in a research note on Tuesday.

Institutional Investors Weigh In On Anixa Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Westside Investment Management Inc. increased its stake in Anixa Biosciences by 151.8% in the 3rd quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock valued at $110,000 after purchasing an additional 21,100 shares in the last quarter. Virtu Financial LLC acquired a new stake in Anixa Biosciences in the third quarter valued at $34,000. Tyler Stone Wealth Management increased its position in shares of Anixa Biosciences by 100.0% in the third quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after buying an additional 21,008 shares in the last quarter. International Assets Investment Management LLC raised its stake in shares of Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after buying an additional 23,800 shares during the last quarter. Finally, Concorde Asset Management LLC purchased a new stake in shares of Anixa Biosciences in the 2nd quarter worth about $31,000. 29.13% of the stock is currently owned by institutional investors and hedge funds.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.